Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer




Annals of Oncology (2019) 30 (suppl_9): ix13-ix19. 10.1093/annonc/mdz418


M. MIKI1, S. Takao2, M. Konishi3, Y. Shigeoka4, M. Miyashita5, H. Suwa6, M. Imamura7, T. Okuno8, K. Hirokaga2, Y. Miyoshi7, K. Murase7, A. Yanai7, K. Yamagami9, K. Akazawa10

Author affiliations

  • 1 Breast Surgical Oncology, Kobe University Hospital, 650-0017 - Kobe/JP
  • 2 Breast Surgical Oncology, Hyogo Cancer Center, 6738558 - Akashi/JP
  • 3 Breast Surgical Oncology, Hyogo Prefectural Nishinomiya Hospital, 6620918 - Nishinomiya/JP
  • 4 Oncology, Yodogawa Christian Hospital, 5330024 - Osaka/JP
  • 5 Breast Surgical Oncology, Konan Hospital, kobe/JP
  • 6 Breast Surgical Oncology, hyogo Prefectural Amagasaki General Medical Center, Amagasaki/JP
  • 7 Breast Surgical Oncology, Hyogo Colledge of Medicine, Nishinomiya/JP
  • 8 Breast Surgical Oncology, Nishikobe Medical Center, Kobe/JP
  • 9 Breast Surgical Oncology, Shinko Hospital, Kobe/JP
  • 10 Medical Infomatics, Niigata University, 9518520 - Niigata/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 47P


When considering treatment for metastatic and recurrent breast cancer, it is necessary to select drugs with emphasis on side effects and QOL. In Japan, oral 5-FU drugs have often been used for initial treatment. In the conventional schedule of S-1 for 4-week administration period followed by 2-week rest, the inferiority of S-1 to T has already been proved. In this study, we examined the efficacy and safety of the schedule of S-1 for 2-week administration period followed by 1-week rest, which is considered to have less side effects and better compliance.


We enrolled individuals with HER2-negative breast cancer who had not received chemotherapy after diagnosis of metastatic breast cancer. S-1 (40-60 mg, twice daily) was administered consecutively for 14 days followed by 7 days of rest (1 course). The primary endpoint was progression-free survival (PFS); the secondary endpoints were overall survival (OS), time to treatment failure (TTF), response rate (RR), disease control rate (DCR), and adverse events.


Between September 1, 2013 and August 31, 2016, 32 patients were enrolled. Median PFS was 7.8 months (1.4-35.4 months), and median OS was 25.2 months (4.8-47.8 months). TTF was 9.1 months. RR was 31.3%, and the DCR was 78%. The cumulative rates of the relative total administration dose of S-1 was 95.6%. Incidence of grade 3 side effects were neutropenia (9.4%), leukopenia (3.1%), anorexia (3.1%), ocular symptoms (3.1%), and an increase in total bilirubin levels (3.1%).


The schedule of 2-week administration period followed by 1-week rest seems to be safe and effective for primary treatment of metastatic and recurrent breast cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Kobe Breast Cancer Oncology Group.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.